YOU ARE EXPLORING
Oncology Biomarkers MSI / MMR
Cancer biomarkers | From findings to interpretation

MSI / MMR

Use of mismatch repair deficiency and MSI-H for immunotherapy decisions and initial Lynch syndrome screening, including assay-specific interpretation.

Clinical context

Biomarker definition and clinical relevance

Mismatch repair defects often cause loss of MLH1, PMS2, MSH2, or MSH6 expression and increased microsatellite instability. MMR immunohistochemistry, MSI-PCR, and validated NGS assays provide related but not identical information; the appropriate method depends on tumor type.

Note for clinicians

Final decisions depend on tumor type, stage, previous therapy, a validated assay result, and current drug indications. This content does not imply availability of a bookable laboratory service.

CLINICAL APPLICATIONS

Clinical applications and result interpretation

01

Selecting immune checkpoint blockade

dMMR or MSI-H can inform checkpoint-inhibitor selection according to tumor type, stage, and drug indication. For colorectal cancer, CAP/ASCO favor MMR IHC and/or MSI-PCR, with appropriately validated MSI-NGS considered an alternative.

Assay and specimen: In CRC, IHC for all four MMR proteins and/or MSI-PCR; validation of NGS against reference methods is important.

Clinical interpretation: Interpret and report MSI/dMMR in the context of tumor type, specimen quality, and internal controls.

02

Endometrial cancer and Lynch syndrome assessment

For endometrial carcinoma, CAP/ASCO favor MMR IHC for mismatch-repair-related treatment decisions. Protein loss patterns can guide referral for hereditary assessment.

Assay and specimen: IHC for MLH1, PMS2, MSH2 and MSH6; when MLH1/PMS2 are lost, consider MLH1 promoter methylation assessment in the appropriate context.

Clinical interpretation: Tumor dMMR alone does not diagnose Lynch syndrome. Somatic causes and MLH1 methylation also need consideration.

03

Discordant MMR and MSI results

Discordance, such as proficient MMR by IHC with MSI-H by a molecular test, calls for review of pathology, block quality, and, where appropriate, repeat or orthogonal testing.

Assay and specimen: Review IHC internal positive controls, tumor fraction, loci or MSI-NGS algorithm, and panel coverage.

Clinical interpretation: High TMB is not a surrogate for dMMR under CAP/ASCO guidance.

INTERPRETATION / LIMITATIONS

Limitations and interpretive notes

• Loss of MLH1/PMS2 and loss of MSH2/MSH6 have different implications for Lynch syndrome investigation.

• Lynch diagnosis requires appropriate germline and clinical evaluation; tumor screening alone is not diagnostic.

• MSI-H, dMMR, and TMB-H are different biomarkers and must not be reported interchangeably.

REFERENCES

Guidelines and references

Discuss a specific molecular scenario

For questions about a clinical scenario, use the support form without including any patient identifiers.

Specialist support form →
WhatsAppCall usGet expert consultation